Humacyte to Participate at Upcoming Investor Conferences in September

Rhea-AI Summary

Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology company, has announced its participation in two upcoming investor conferences in September 2024. The company, which focuses on developing universally implantable, bioengineered human tissue at commercial scale, will be represented by Laura Niklason, M.D., Ph.D., Founder, President, and CEO, and Dale Sander, CFO.

The conferences are:

• H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 11, 2024, from 8:30 - 9 AM ET
• Cantor Global Healthcare Conference on Wednesday, September 18, 2024, from 9:10 - 9:40 AM ET

Both events will feature company presentations, with webcasts available for interested parties to view online.

News Market Reaction

-8.51%

1 alert

-8.51% News Effect

On the day this news was published, HUMA declined 8.51%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following conferences in September.

H.C. Wainwright 26th Annual Global Investment Conference
Format: Company Presentation
Date: Tuesday, September 11, 2024
Time: 8:30 – 9 AM ET
Webcast: https://journey.ct.events/view/

Cantor Global Healthcare Conference
Format: Company Presentation
Date: Wednesday, September 18, 2024
Time: 9:10 – 9:40 AM ET
Webcast: https://wsw.com/webcast/cantor22/huma/

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FAQ

When is Humacyte (HUMA) presenting at the H.C. Wainwright Global Investment Conference in 2024?

Humacyte (HUMA) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 11, 2024, from 8:30 - 9 AM ET.

What is the date and time for Humacyte's (HUMA) presentation at the Cantor Global Healthcare Conference in 2024?

Humacyte (HUMA) is scheduled to present at the Cantor Global Healthcare Conference on Wednesday, September 18, 2024, from 9:10 - 9:40 AM ET.

Who will be representing Humacyte (HUMA) at the September 2024 investor conferences?

Laura Niklason, M.D., Ph.D., Founder, President, and CEO, and Dale Sander, CFO, will be representing Humacyte (HUMA) at the September 2024 investor conferences.

What is Humacyte's (HUMA) main focus as a biotechnology company?

Humacyte (HUMA) is a clinical-stage biotechnology company focused on developing universally implantable, bioengineered human tissue at commercial scale.

Are webcasts available for Humacyte's (HUMA) investor conference presentations in September 2024?

Yes, webcasts are available for both of Humacyte's (HUMA) investor conference presentations in September 2024. Links to the webcasts are provided in the press release.